CompletedNCT00434213
Skin reactions to methylphenidate patches in children with ADHD
About this title
Read the official source — NCT00434213Medication studyAges 6–12United States
Understand this study
Who was this study for?
Listed age limits: 6 years to 12 years.
- Listed locations
- Scottsdale and 28 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJanuary 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 309
- Sponsor
- Noven Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT00434213
- Official title
Show the full official title
A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD).
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Scottsdale · Irvine · San Marcos
26 more locations
- Spring Valley
- Wildomar
- Boulder
- Gainesville
- Miami
- Winter Park
- Libertyville
- Northbrook
- Overland Park
- Bardstown
- Owensboro
- Cambridge
- Kalamazoo
- Las Vegas
- Toms River
- Rochester
- Cleveland
- Columbus
- Portland
- Salem
- Philadelphia
- Jackson
- Austin
- Lubbock
- San Antonio
- Norfolk
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Noven Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Daytrana.
Who was this study for?
Listed age limits: 6 years to 12 years.
